Podcasts about Cart

Do the 2001 Patriots compare to the 2025 Patriots in significant ways? // Former Patriots' QB Brian Hoyer joins, says Pats are the real deal // Comparing Maye to Brady //

Editor-in-Chief of Molecular Therapy, Dr. Joseph Glorioso, is joined by Rachael Nimmo, PhD, former director of the Cell Technology Group at Oxford Biomedica, and Kyriacos Mitrophanous, PhD, Chief Innovation Officer at Oxford Biomedica, to discuss an article recently published in Molecular Therapy by Nimmo and colleagues titled “Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector.” Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

HOUR 4: ARE THE CART CORRALS AFFIXED OR NOT AFFIXED?! That is the question. full 2118 Mon, 10 Nov 2025 23:00:00 +0000 BYpLLrNBGkJzXjHRjldrmzcuuqbqEygf news The Dana & Parks Podcast news HOUR 4: ARE THE CART CORRALS AFFIXED OR NOT AFFIXED?! That is the question. You wanted it... Now here it is! Listen to each hour of the Dana & Parks Show whenever and wherever you want! © 2025 Audacy, Inc. News False https://player.am

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML). Join us as we delve into: • An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. • Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias. • Unique side effects associated with each TKI and strategies for dose optimization. • The importance of patient education and monitoring to ensure effective management of side effects. Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care! #CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine

Memory chip stocks like SanDisk (SNDK), Seagate (STX) and Western Digital (WDC) gathered more bullish traction from firms like Loop Capital and Barclays. Diane King Hall explains where the Street is seeing more upside for these companies and the role A.I. plays in their theses. Healthcare stocks dipped after President Trump made comments against health insurers on Truth Social. Diane later turns to Instacart's parent company, Maplebear (CART), which delivered a double-win in earnings through a beat and share buyback announcement.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

En este capítulo exploramos cómo la terapia génica ha dejado de ser una promesa para convertirse en una herramienta real dentro de la medicina. Analizamos dos avances recientes que lo demuestran: la recuperación de la audición en niños con sordera congénita mediante la introducción de una copia sana del gen OTOF, y las terapias CAR-T, que reprograman células del sistema inmunitario para atacar ciertos tipos de cáncer resistentes. También abordamos los retos que plantea esta revolución, desde la producción hasta la financiación y la sostenibilidad del sistema sanitario. Nos lo cuenta Paula Río, investigadora del CIEMAT y presidenta de la Sociedad Española de Terapia Génica y Celular.

Sonhos videntes, cartoes perdidos e pantufas

Drafting players based on their week 1 performances! A top 25 twinvestigation! Bold predictions for this weekend's marquee matchups! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Scottish Psalter | Richard Sibbes | Forgetting by Tim Schaufert | The Baker's Cart by Jean Michelin | Find more at www.ryanbush.org

In this latest episode of Wellness Junkies, we're diving into our newest product crushes - all tested, tried, and totally worth it. We're so excited to be back sharing the things we're genuinely loving lately. From viral TikTok finds to everyday staples that actually make a difference, this episode is all about the products helping us feel (and look) our best right now.We've been testing everything we talk about for at least three months, so these aren't just first impressions - they're real results from products that earned a spot in our routines. Expect honest reviews, fun discoveries, and a few surprises along the way.If you're in the mood for a little inspiration (and maybe a few new favorites), grab your matcha and tune in, because we did the testing so you don't have to. We hope you love this Product Junkies episode as much as we loved recording it - and maybe find a new favorite (or two) to add to cart.Brands/Mentions + Shop this episode: Shop here ⁠⁠⁠⁠⁠⁠For More on this Episode: Read the full show notes ⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠Join the community:Follow us ⁠⁠⁠⁠⁠@wellnessjunkiesofficial ⁠⁠⁠⁠⁠on InstagramSubscribe to our newsletterShop this episode + our faves on ⁠⁠⁠⁠⁠ShopMyShop⁠⁠⁠⁠⁠NEW! Follow us @wellnessjunkies on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠ and TikTokFollow Amy @amynicolle on TikTokVisit ⁠www.wellnessjunkiesofficial.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Shop our Amazon Store⁠⁠⁠⁠⁠Say hi: ⁠⁠⁠⁠⁠⁠⁠⁠⁠press@wellnessjunkiesofficial.com⁠⁠Please subscribe, rate, review + share to help us grow the community

We love to hear from our listeners. Send us a message.Episode 115 of Cell & Gene: The Podcast features Host Erin Harris' talk with Aliya Omer, Vice President and Global Head of Hematology and Cell Therapy at AstraZeneca. Omer shares valuable insights from her rich experience leading cell therapy development across multiple top companies. She highlights the critical importance of collaboration by breaking down silos across research, manufacturing, regulatory, and commercial teams to deliver innovative therapies efficiently. She also discusses AZ's diverse and ambitious cell therapy portfolio, encompassing autologous CAR-T, TCR-T, in vivo gene therapies, and regulatory T-cell therapies. She candidly addresses current challenges in manufacturing scalability, patient access, and healthcare system readiness and describes how AZ is prioritizing fast manufacturing platforms and ecosystem-wide partnerships to surmount these hurdles. Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Dr. Monty Pal and Dr. Pauline Funchain discuss the latest efforts to diagnose, prevent, and treat the series of immune-related adverse events that have emerged in the era of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I am Monty Pal, a medical oncologist, professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles, California. Now, it is probably no surprise to this audience that immunotherapy has transformed the treatment landscape for multiple cancer types. It remains a pillar of modern oncology. Having said that, I think we have all been baffled by certain toxicities that we run into in the clinic. Today, I am delighted to be joined by Dr Pauline Funchain to discuss some of the checkpoint inhibitor toxicities that people struggle with most. And we will also touch on some side effects of immunotherapy beyond checkpoint inhibitors: CAR-T cells, bispecifics, so on and so forth. Dr Funchain is a dear friend, and she is an associate professor and associate director of cancer research training and education at the Stanford Cancer Institute. She is co-director of the Immunotherapy Toxicity Program and the Skin Cancer Genomics Program at Stanford, where she also serves as associate program director of hematology and oncology fellowship. Dr. Funchain is also the co-founder of ASPIRE, and we are going to talk about that a little bit today, the Alliance for the Support and Prevention of Immune-Related Events. FYI for listeners, if you are interested in our disclosures, they are available at the transcript of this episode. Pauline, thanks so much for joining us today. Dr. Pauline Funchain: Monty, thank you for this invitation. It is always great to talk. Dr. Monty Pal: So, for the audience, Pauline and I know each other from my days as a fellow at City of Hope. She was a resident at Harbor UCLA and a stellar resident at that. It has just been amazing to sort of see your career grow and blossom and to witness all the cool things that you are doing. ASPIRE, in particular, sort of caught my eye. So again, for listeners, this is the Alliance for the Support and Prevention of Immune-Related Events. Can you tell us a little bit briefly about the genesis of that, how that came about? Dr. Pauline Funchain: So, there was a bunch of us who were really struggling, I mean, all of us have struggled with these immune-related adverse events, these irAEs. You know, they are new disease states, and even though they look like autoimmune diseases, they tend to need a whole lot more steroid than autoimmune diseases do and they do not totally present in the same way. And in fact, you know, Triple-M, or Triple-M overlap syndrome, is a completely new irAE, a new immune state that we have never had before the advent of checkpoint inhibitor. And so a Triple-M, for those of you who are not as familiar, that is the constellation of myocarditis, myositis, and myasthenia gravis, something that never occurs as a natural autoimmune disease. So we were starting to realize that there were some major differences with these irAEs and autoimmune diseases. We could not treat them the right way. We really needed to learn more about them. And a bunch of us who had interest in this said, "Look, we really need to be all in one space to talk about what we are doing," because all of our treatments were our own little homegrown brews, and we needed to really get together and understand how to treat these things, how to diagnose them, and then learn more about them. So, Dr. Alexa Meara from Ohio State, Dr. Kerry Reynolds from Mass Gen, we put together this research consortium, brought together all of our irAE friends, got our best subspecialists together in a research consortium, which is now only about a year and a half old. And we made this research consortium, the Alliance for Support of Prevention of Immune-Related Events, and we reached out to ASCO, and ASCO was so kind to grant us a [Alliance for Support and Prevention of Immune-Related adverse Events (ASPIRE)] Community of Practice. So we met for the first time as a Community of Practice at the ASCO Annual Meeting just this past June and really got an ASCO community together to really think about how to again, diagnose, prevent, treat irAEs. Dr Monty Pal: This is interesting to me. The ASCO Community of Practice phenomenon is something that I was not super familiar with. Can you explain to our listenership what is the ASCO Community of Practice model? If you have particular interests, how do you sort of get one started? Dr Pauline Funchain: Yeah, so ASCO has an entire page on their Community of Practice. There are multiple Community of Practice groups or COPs. There are ones for Supportive Oncology and Survivorship. There is Women in Oncology. There is a group for International Medical Graduates. And there is about, I think 10 or 12 now that have a physical presence at ASCO but also a virtual presence on the ASCO Community of Practice site. So, if you were interested in any one of these, and you can see them on the ASCO Communities of Practice sites, you would ask to become a member. Once granted membership, then there is a whole webpage of postings and conversations that people can have. You can get email digests of conversations that happen on the website, and then you can anchor it with in-person participation at the Annual Meeting. Dr Monty Pal: That is awesome, and I can think of so many different foci within oncology that really sort of deserve a Community of Practice. This definitely being one of them. You know, it strikes me as being so interesting. I mean, the checkpoint inhibitors have been around for a while now. I think when you and I were in training, gosh, back then, these were just a little bit of a pipe dream, right? But having said that, I would probably say that more than half of my kidney cancer practice is either on checkpoint inhibitors, and the vast majority have been on one at some point in their past, right? With that in mind, you know, we have all treated a lot of patients with these drugs. Why is it that we still struggle to manage the toxicities? And just to take that one step further, what are some of the toxicities that, perhaps through ASPIRE or through your experience, people struggle with the most? Dr Pauline Funchain: So, I think we are still struggling with these because again, they are new disease states, right? This is what we all experienced with COVID, a brand-new virus and a brand-new syndrome. We now have 20-plus of these as irAEs. And what we have realized about them is the immune activation that happens with these is so much more than what we have seen with autoimmune diseases. So for instance, if you have a Crohn's or ulcerative colitis, you will top out at 40 to 60 milligrams of prednisone if a Crohn's flare or ulcerative colitis flare happens. But for our severe IR colitises, you know, it is at least 1 mg per kg, often goes up to 2 mg per kg. We, in some cases, have done 1 gram pulses if we are worried that somebody is going to perforate. So that was sort of like the first 5 years of treating irAE, and then now in the sort of second 5 years of treating irAE, we have realized that that is a lot of immunosuppression, and we might be able to get away with less with the newer biologics that are on board. So, we are struggling to try to get the data for some of these irAEs that we knew, we have known for a while, but to try to get newer treatments that may immunosuppress less so that you may still be able to retain that tumor response. And in fact, some of the preclinical studies suggest that some of these biologics may actually synergize with the immunotherapy and actually make the immunotherapy more effective from a tumor perspective and calm down the irAE as sort of the bystander effect. So we are still trying to optimize those. Getting up trials in the space has been very difficult. That is one of the reasons for the genesis of ASPIRE because we realized we needed to band together to have a bigger voice in that realm. Then there are other things that are brand new. So we talked about Triple-M. So Triple-M, again, with Triple-M or any myocarditis or myasthenia, I mean, there is about a 50% chance of death from irAE based on the literature. I think we are getting better at recognizing this, and so at Stanford we have some data to say that if you serially follow troponin, that maybe your outcomes are better. You can potentially lower the percentage of cases that are fatal because you can catch them early. I mean, this is all preliminary data, but again, these are all things that are evolving, and we do not all have the right answer. I mean, even the serial troponin thing, I think, is pretty controversial. And in fact, at one of our quarterly Zoom meetings that we are doing in ASPIRE in December is going to sort of flush out that controversy about serial troponin measuring and what is the best thing to use? Would you use something like abatacept or would you use ruxolitinib? Which one is better? I think there is a lot of controversy still about these things. Dr Monty Pal: You have really piqued my curiosity here because you think about the cons of treating irAEs, right? And I worry exactly about what you had mentioned, right, which is, "Gosh, what is going on with this tumor in terms of immunosuppression?" But you think about some of the newer agents, you mentioned ruxolitinib, I have heard of dasatinib, for instance, in this setting. Frankly speaking, a lot of these, as you point out, are really thought of as being also anticancer drugs. So you have really got me thinking about the potential synergy between perhaps suppressing an irAE and augmenting antitumor activity, which I think is very interesting. Am I on the right track with that? Dr Pauline Funchain: I think so, but you will find that a lot of people will not even go there because they are worried about how much immunosuppression you are going to cause. I am at heart a geneticist, but I think an immunologist will happily tell you that the immune system is very complex. There are multiple pathways, and these drugs do not all target the same immune pathways. So if we understand a little bit more about the pathways we are targeting and pick apart the pathways that are really, really tumor relevant and the other pathways that are not tumor relevant, you may be able to piece together a better marriage of tumor response and irAE control. Dr Monty Pal: Kind of on this topic, and again, leaning on your background in genetics, where are we in terms of predicting these irAEs? I mean, you would think the holy grail would be picking out a snip or something of this for it, right, that could potentially identify that patient who is going to get Triple-M or, you know, at the very least a significant high-grade irAE event. Are we anywhere closer to that in 2025? Dr Pauline Funchain: There have been data published. There have been some big GWAS studies. All of the effect sizes are pretty small. So there are some prediction algorithms, but none of them are clinically useful. And I think when you look at the odds ratios, they will increase risk by maybe 20%. I think one of the things that we found in a very small series and supported anecdotally is something as easy as family history of autoimmune disease is probably more predictive at this point than any of those types of markers. I think we will get there, but we are not anywhere near where we would like to be. Things like TMB also, actually, there is some good data about higher TMB, higher risk of irAE too. Dr Monty Pal: Interesting. I see all this data coming through, IL-8 polymorphisms, etc. And I just wondered if any of that was ready for prime time. But I mean, this is a good message for the practicing clinician. Sounds like we are not quite there yet. And I could probably keep you on for another entire podcast to talk about this topic, but let us see if we can at least skim the surface. I never thought I would see the day when BiTEs and CAR-Ts were entering into my kidney cancer practice, but in fact, it is really become central to a lot of our clinical trials in RCC these days. I would be lying if I did not say that I was not struggling with the toxicities and so forth associated with these drugs. Can you give us a quick primer, maybe just good resources that people can go to for managing toxicity with BiTEs and with CAR and with some of these novel therapeutic modalities that we are using in the oncology clinics? Dr Pauline Funchain: I know there is a recently published toxicity manual for BiTEs in hematologic malignancies, I think it was in Blood. CAR-T is covered in many irAE guidelines. So ASCO guidelines actually has a CAR-T [cell therapy guideline], and I would be remiss not to point out that actually ASCO has a, I am a little biased, but a wonderful guideline on irAE that is actually being updated as we speak. We are hoping for publication next year. I find the format of that, there are many guidelines out there, actually. There is ASCO, SITC, ESMO has a guideline for irAE, but I find the formatting of the ASCO guideline to be much easier to flip through during clinic, just because of the visual format of the tables. But that is going to be updated next year. And with CAR-T, there is now multiple publications also in terms of guidelines. But what I will say about bispecifics and CAR-T, so they have very similar toxicities in terms of the cytokine release and also with the ICANS, so the neurotoxicity. But what we have been finding that is really interesting with BiTEs and CAR-T, and actually even with TIL, cytokine release is very similar to some of the IL-2 toxicities but not identical that we see with TIL treatment. But now we are starting to see overlap. So patients who have been treated with immunotherapy and then go on to get a bispecific or then go on to get TIL, so I have seen some colitises that have occurred after the fact. Some of the newer CAR-Ts without checkpoint have been causing some really interesting, probably not in a good way, but interesting biologically, colitises that are really refractory. So we are starting to see some overlap, and again, I think this field is just evolving constantly. Dr Monty Pal: Yeah, no, I almost think I need to go back to that fellowship that you and I did together 20 years ago and, you know, and see if I could repeat some coursework on CAR-T management.  You know, Pauline, I could probably keep you on the horn for hours, but this has just been terrific. Thank you so much for sharing all of your insights with us today on the ASCO Daily News Podcast. Dr Pauline Funchain: Thank you for the invitation. It was wonderful to talk about this, and it was wonderful to catch up a little bit, Monty. Dr Monty Pal: Same here, same here. And thanks to our listeners too. If you value the insights you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:      Dr. Monty Pal    @montypal   Dr. Pauline Funchain @FunchainMD Follow ASCO on social media:       @ASCO on Twitter      ASCO on Bluesky     ASCO on Facebook       ASCO on LinkedIn     Disclosures: Dr. Monty Pal:     Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview    Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical    Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis    Dr. Pauline Funchain: Consulting or Advisory Role: Merck, Replimune, Sanofi/Regeneron, Immunocore, Tempus Research Funding (Inst.): Pfizer, Bristol-Myers Squibb, IDEAYA Biosciences, Linnaeus Therapeutics Travel, Accommodations, Expenses: Merck

In this value-packed episode, e-commerce expert Matthew Stafford shares how understanding and responding to real customer data powers dramatic business growth and website conversion lifts. Matthew describes his journey from ad specialist to conversion optimization guru—driven by necessity, continuous learning, and a genuine passion for data-driven problem-solving. Together with Jeff Mains, they dive into practical strategies for removing friction from your site, the science of micro-commitments, actionable post-purchase surveys, and how to build websites that truly speak to your ideal customers. Whether you're in SaaS or e-commerce, this episode delivers actionable steps to boost conversions, collect meaningful insights, and lead your team to sustained success.Key TakeawaysThe Power of Website Data (00:00:00)Deeply understanding what users actually do on your site beats guessing or bias. Data is “agnostic” and reflects real user behavior.Solve the Right Problems with Data-Driven Insights (00:01:05)Tracking analytics turned Matthew's declining sales around from loss to profitability.Post-Purchase Surveys Drive Revenue (00:05:01)Implement a simple post-purchase question: “What almost stopped you from buying?” The answers lead to multi-million dollar wins.Micro-Commitments & Button Text (00:13:11)“Buy now” creates friction. Instead, use action-specific steps like “Add to Cart” or “Learn More” to lead customers smoothly to purchase.Focus on Simplicity & Clarity (00:10:43)Clarity always trumps persuasion. Present the next necessary action clearly and reduce choices to avoid customer confusion.Start Optimization at the Checkout, Work Backwards (00:27:51)Always optimize conversion pages (checkout, cart, product page) before iterating on the homepage or filters.Tweetable Quotes"The data is agnostic. It doesn't care what you're thinking—it just tells you exactly what they're doing." —Matthew Stafford"Clarity trumps persuasion. Make your site so simple that Homer Simpson would understand it." —Matthew Stafford"If you describe the problem better than your customer can, they'll assume you have the solution." —Matthew Stafford"Stop treating customers like transactions. Treat them like your mom—build real relationships." —Matthew Stafford"People don't want to click on a button if they don't know where it's taking them. Make every step clear." —Matthew Stafford"You don't have a brand until you can stop running ads and survive. Until then, you just have a good funnel." —Matthew StaffordSaaS Leadership LessonsBe Willing to Learn Before DelegatingMatthew learned analytics himself before hiring, allowing him to hire better and direct vision with confidence.Let Data Be Your GuideRemove ego and personal preference; let unbiased customer data inform and drive your decisions.Prioritize Problems with Greatest Revenue ImpactStart optimization where money changes hands, not where you “feel” the problem is.Don't Redesign for VanityAvoid unnecessary redesigns driven by boredom or internal desire for novelty; new visitors see your site for the first time.Embrace Customer ConversationsReal feedback, surveys, and live chats are goldmines for improvement and repeat sales.Iterate with Focused ExperimentsTest, don't guess: collect feedback, run tests on focused elements, and double down on what specifically works.Guest...

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Download the transcript here

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Listen to the podcast here

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-cell lymphoma in a study with 245 patients. Findings show a tentative way forward in treatment for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Featured Article:Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Pedro Henriques considera que a equipa de arbitragem e o VAR deviam ter dado cartão amarelo a Gabi Veiga e a Barkas. Dá nota 5, uma arbitragem positiva, com cartão vermelho mal mostrado.See omnystudio.com/listener for privacy information.

Il aura fallu au Maroc cinquante ans de travail diplomatique avant de voir le conseil de sécurité de l'ONU lui apporter son soutien au sujet du Sahara occidental. Un tournant décisif qui a fait de grands perdants : les Sahraouis du front Polisario et leur fidèle soutien, l'Algérie. Mention légales : Vos données de connexion, dont votre adresse IP, sont traités par Radio Classique, responsable de traitement, sur la base de son intérêt légitime, par l'intermédiaire de son sous-traitant Ausha, à des fins de réalisation de statistiques agréées et de lutte contre la fraude. Ces données sont supprimées en temps réel pour la finalité statistique et sous cinq mois à compter de la collecte à des fins de lutte contre la fraude. Pour plus d'informations sur les traitements réalisés par Radio Classique et exercer vos droits, consultez notre Politique de confidentialité.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Revolutionizing Retail: Drew Ann Long's Caroline's Cart Journey In this episode of 'Why Not Me', hosted by Tony Mantor from Nashville, Tennessee Drew Ann Long shares her inspiring story of creating Caroline's Cart—a revolutionary shopping cart designed for individuals with special needs. Drew Ann, motivated by her daughter Caroline's severe disabilities, overcame numerous challenges, financial hurdles, and industry skepticism to bring her vision to life. Despite initial rejections from manufacturers, Drew's relentless pursuit led to global recognition and adoption of Caroline's Cart, transforming accessibility in retail. She also discusses the formation of Caroline's Cause, a nonprofit providing scholarships to families with special needs children. Drew's journey highlights the impact of empathy-driven innovation and the importance of taking bold risks to make a difference. Meet Drew Ann Long: Founder of Caroline's Cart The Birth of Caroline's Cart Challenges and Breakthroughs The First Prototype and Social Media Explosion Manufacturing Struggles and Success Nationwide and International Expansion Caroline's Cause: Giving Back Future Plans and Continued Growth Closing Thoughts and Contact Information Music written By T. Wild Mantor Music BMI The content on Why Not Me: Embracing Autism amd Mental Health Worldwide, including discussions on mental health, autism, and related topics, is provided for informational and entertainment purposes only. The views and opinions expressed by guests are their own and do not reflect those of the podcast, its hosts, or affiliates.Why Not Me is not a medical or mental health professional and does not endorse or verify the accuracy, efficacy, safety of any treatments, programs, or advice discussed.Listeners should consult qualified healthcare professionals, such as licensed therapists, psychologists, or physicians, before making decisions about mental health or autism- related care.Reliance on this podcast's contents is at the listener's own risk. Why Not Me is not liable for any outcomes, financial or otherwise, resulting from actions taken based on the information provided. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

Federico Cartín es director ejecutivo de la asociación Costa Rica por Siempre, una organización privada sin fines de lucro que busca proteger los ecosistemas marinos y terrestres a través de la gestión de fondos y alianzas con gobiernos, el sector privado y la sociedad civil  En este episodio, Federico conversó con la profesora Andrea Prado acerca de los fondos de conservación en Costa Rica, así como del impacto y potencial que tiene la economía azul para nuestra región. El podcast Gerente de Impacto es dirigido por la Prof. Andrea Prado y producido por la Cátedra Strachan de INCAE Business SchoolEscúchelo en: 

Ecoutez L'édito d'Etienne Gernelle du 04 novembre 2025.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

From checkout to cart to the Customer Portal, this release streamlines the buyer journey and gives you more control behind the scenes. Think fewer upgrade headaches, cleaner customer touchpoints, and...

Arlette Chabot a écouté toutes les déclarations de Marine Le Pen, de Jordan Bardella sur les débats budgétaires, sur les impôts, sur les taxes et sur la dépense publique. C'était difficile à suivre ces derniers temps. Elle dit que c'est un grand écart, on a du mal à se retrouver. Pour Dominique Seux, il y a des exemples qui montrent que les taxes ont des incidences économiques, voire industrielles, c'est l'aviation d'affaires. Ce n'est pas que le secteur ne l'intéresse pas en tant que tel, mais c'est un enseignement qui montre que les meilleures intentions du monde peuvent aboutir à une catastrophe. Celui que l'on appelait le vice-président le plus détesté de l'histoire américaine est l'exemple le plus spectaculaire de ce que la morale peut faire comme ravage. Selon Abnousse Shalmani, Dick Cheney est devenu un symbole d'intégrité loué par les démocrates, tout simplement parce qu'à la fin de sa vie, il s'est prononcé contre Donald Trump. Du lundi au vendredi, à partir de 18h, David Pujadas apporte toute son expertise pour analyser l'actualité du jour avec pédagogie.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Sánchez comparece en el Senado y califica la comisión de circo, evadiendo preguntas clave con un recurrente "no me consta". Se le acusa de encenagamiento político y de no ofrecer explicaciones convincentes sobre su presunta implicación en casos de corrupción. En Pamplona, cuatro argelinos son detenidos por agresión sexual y robo. El embajador de Japón en España, Takahiro Nakamae, finaliza su misión, siendo reconocido por su dedicación al país. Se analiza que Sánchez sale vivo de la comparecencia, pero acorralado y sin ofrecer claridad. La inflación se dispara, afectando la luz, viajes y billetes de tren. En deportes, se juega la Copa del Rey y la Liga. A nivel internacional, Trump anuncia la reanudación de pruebas nucleares y se observa un deshielo comercial entre EE.UU. y China. El Hospital de La Paz presenta una terapia pionera con células CAR-T para la leucemia infantil, logrando resultados esperanzadores. COPE informa sobre la agenda de Madrid, incluyendo un dispositivo de ...

-SNAP benefits are running out due to the Schumer Shutdown, and Rob suggests giving to your local food bank — or preparing to ankle-tackle grocery thieves like a patriotic linebacker. -Between rants about the bourgeoisie, fentanyl, and golf carts, Rob declares the Democrat Party dead, buried, and possibly returning as a zombie by the midterms. Today's podcast is sponsored by : BEAM DREAM POWDER : Improve your health by improving your sleep! Get 40% off by using code NEWSMAX at http://shopbeam.com/NewsmaxGET FRESH OLIVE OIL : Try real farm fresh olive oils for FREE plus $1 dollar shipping at http://GetFreshRobCarson.comBIRCH GOLD - Protect and grow your retirement savings with gold. Text ROB to 98 98 98 for your FREE information kit! To call in and speak with Rob Carson live on the show, dial 1-800-922-6680 between the hours of 12 Noon and 3:00 pm Eastern Time Monday through Friday…E-mail Rob Carson at : RobCarsonShow@gmail.com Musical parodies provided by Jim Gossett (www.patreon.com/JimGossettComedy) Listen to Newsmax LIVE and see our entire podcast lineup at http://Newsmax.com/Listen Make the switch to NEWSMAX today! Get your 15 day free trial of NEWSMAX+ at http://NewsmaxPlus.com Looking for NEWSMAX caps, tees, mugs & more? Check out the Newsmax merchandise shop at : http://nws.mx/shop Follow NEWSMAX on Social Media:  -Facebook: http://nws.mx/FB  -X/Twitter: http://nws.mx/twitter -Instagram: http://nws.mx/IG -YouTube: https://youtube.com/NewsmaxTV -Rumble: https://rumble.com/c/NewsmaxTV -TRUTH Social: https://truthsocial.com/@NEWSMAX -GETTR: https://gettr.com/user/newsmax -Threads: http://threads.net/@NEWSMAX  -Telegram: http://t.me/newsmax  -BlueSky: https://bsky.app/profile/newsmax.com -Parler: http://app.parler.com/newsmax Learn more about your ad choices. Visit megaphone.fm/adchoices

Pedro Sánchez comparece en la comisión de investigación del Senado, donde el PP critica su actitud evasiva y su falta de colaboración. Sánchez acusa a la ultraderecha de atacar a las mujeres. Se analizan las consecuencias de esta comparecencia, con los aliados de Sánchez considerando que sale "indemne" y la oposición pidiendo su dimisión. Carlos Mazón, presidente de la Generalitat Valenciana, reflexiona sobre un evento pasado que genera más peticiones de dimisión. En noticias internacionales, se informa sobre un acuerdo entre Trump y Xi, la entrega de cuerpos por parte de Hamás, ataques rusos a Ucrania y detenciones por el robo del Louvre. A nivel nacional, cuatro detenidos por agresión sexual en Pamplona ingresan en prisión. La inflación de octubre sube al 3.1%. Se informan de complicaciones de tráfico en Madrid. El Hospital de la Paz anuncia un avance con células CAR-T en niños con leucemia. Miguel Tellado del PP critica duramente a Sánchez y su gobierno, afirmando que está ...

In this Review Series episode, Associate Editor Dr. Philippe Armand speaks with multiple authors about what it might look like to improve treatments follicular lymphoma, a disease that has been put on the backburner of innovation due to its generally treatable nature. Dr. Armand discusses "Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?" with author Dr. Carla Casulo,  "The future of follicular lymphoma management: strategies on the horizon” with author Dr. Sarah C. Rutherford, and "An updated understanding of follicular lymphoma transformation” with Dr. Erin M. Parry.Find the whole review series on follicular lymphoma in volume 146 issue 15 of Blood Journal.  

Senator Nessa Cosgrove on why she took her own 'snack cart' onto the Sligo train.

In this episode, we dive into how to run the best promotions for Black Friday and Cyber Monday (BFCM). Nathan Ho, Product Manager of EasyGift, shares his experience and advice on structuring promotions, using tiered spending to increase average order value, and the power of free gifts. He also discusses different marketing strategies like scheduled rules and audience targeting to maximize sales during the busiest shopping days.Topics discussed in this episode:  How to start preparing for Black Friday as early as possible.What tiered minimum spend promotions are and why they work.Why a free gift is a strong trigger to encourage customers to buy more.How to use gifts as product samples to introduce new items.What scheduled rules are for setting time-specific deals.How to simplify promotions to avoid confusing your customers.What the classic promotion triggers are: cart value, products, and collections.How to use magic links to target new customers from ads.Why testing promotions before launch is critical to avoid conflicts.What optimizing shipping can do to stand out from competitors.Links & Resources Website: https://www.506.io/easygiftShopify App Store: https://apps.shopify.com/gifter-cart-auto-includeLinkedIn: https://www.linkedin.com/company/506-io/X/Twitter: https://twitter.com/506_appsGet access to more free resources by visiting the show notes at https://tinyurl.com/ab8jb8p3______________________________________________________ LOVE THE SHOW? HERE ARE THE NEXT STEPS! Follow the podcast to get every bonus episode. Tap follow now and don't miss out! Rate & Review: Help others discover the show by rating the show on Apple Podcasts at https://tinyurl.com/ecb-apple-podcasts Join our Free Newsletter: https://newsletter.ecommercecoffeebreak.com/ Support The Show On Patreon: https://www.patreon.com/EcommerceCoffeeBreak Partner with us: https://ecommercecoffeebreak.com/partner-with-us/

This week Emily gets artsy over the man behind CARTdepartment.         SHOW NOTES: Larry Warsh interview Jay Z, Kanye West Otis music video Lots of CART car pics  @cartdept Recorded, edited & mixed by Emdognightmare & Queen of the Vans Production & research Queen of the Vans & Emdognightmare Find us: Car Krush Stay updated w/ our newsletter Hugs, thank you & high fives to Greg Meleney for the killer tunez!

Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That's the second biggest buy of the year after Johnson & Johnson's January acquisition of Intra-Cellular. The Avidity buy could read through positively to Dyne Therapeutics, as both are aiming to treat neuromuscular ailments with RNA-targeting therapies. Dyne shares have nearly doubled over the past month, jumping approximately 40% after Novartis' news dropped.  The Avidity deal is the latest in an uptick on the pharma M&A front. Also this week, Eli Lilly doubled down on gene therapy with a pick up of Adverum Biotechnologies and its lead program for wet age-related macular degeneration. And Roche, which last month acquired 89bio in a $3.5 billion deal centered on a MASH candidate, said in its third-quarter earnings call on Thursday that more deals could be in the future. Finally, beyond the big guys, Leerink Partners predicts which small- to mid-cap firms might also be on the hunt for new pipeline goodies.  Following the dealmaking news, Novartis held its earning call on Tuesday. CEO Vas Narasimhan downplayed the deals Pfizer, AstraZeneca and Amgen have made with the White House, saying they don't address the root of the drug pricing problem President Donald Trump hopes to solve.   On other earnings calls, BioMarin announced plans to divest the hemophilia gene therapy Roctavian. Regeneron faced further questions about Eylea and issues with the Catalent plant that's been tripping up its regulatory applications. But the company didn't address last week's news that it was dropping a CAR T asset picked up from 2seventy bio. These are but two of the latest examples of underperforming assets in the cell and gene therapy space.  BridgeBio had positive news for patients with limb-girdle muscular dystrophy this week after acing a Phase III trial for an investigational substrate supplementation therapy. Analysts predict the asset could be before the FDA later this year or early next.   Finally, with the U.S. government shutdown going on a month, BioSpace takes a look at how the FDA is operating. 

durée : 00:05:32 - Le Billet politique - par : Stéphane Robert - Le Premier ministre, Sébastien Lecornu, estime qu'il n'a plus besoin du Sénat pour élaborer et faire adopter le budget de l'année prochaine. Il fait désormais le pari qu'il peut trouver une majorité à l'Assemblée nationale.

This month, the gals are joined by Trevin from Live, Laugh, Larceny Podcast to discuss a wiener catastrophe, poop spray damage, Sierra's stains, litter at the country club, a food critic for the people, and the most accident-prone pastor you've ever heard of. Tune in for October's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

Radio Foot à 16h10-21h10 T.U. à la Une ce lundi : - Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! ; - Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! Un an et demi de disette pour les Blancos, une première référence pour les Merengue et Xabi Alonso. Sans Raphinha ni Lewandowski, l'homme en forme des Blaugranas, Fermin Lopez, a permis aux Catalans de revenir. Mbappé décisif, même si le Kyks a vu Szczesny stopper sa tentative de penalty. Le but refusé de la 12è minute. Une célébration de courte durée. La frustration du hors-jeu semi-automatique ? Autre frustration, celle de Vinicius Jr, remplacé par Rodrygo à 20 minutes de la fin. - Lamine Yamal bien muselé par Alvaro Carreras, une fin de match sous tension. Le Real en profite pour se détacher, compte 5 points d'avance sur son rival catalan.   Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? L'OM s'était installé dans le fauteuil de leader, mais encaisse une 2è défaite d'affilée. Après la déconvenue du Sporting en C1, les Phocéens battus à Lens. Ils n'auront gardé l'avantage que 7 minutes. Nouvelle soirée de cauchemar pour Benjamin Pavard, après celle de Lisbonne mercredi dernier. On n'arrête plus les Sang et Or de Pierre Sage, qui s'emparent de la 2è place, la 10è journée se joue mercredi. Pour débattre avec Hugo Moissonnier, Manu Terradillos, Hervé Penot et Dominique Sévérac. Technique/réalisation : Laurent Salerno - Pierre Guérin.

Radio Foot à 16h10-21h10 T.U. à la Une ce lundi : - Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! ; - Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! Un an et demi de disette pour les Blancos, une première référence pour les Merengue et Xabi Alonso. Sans Raphinha ni Lewandowski, l'homme en forme des Blaugranas, Fermin Lopez, a permis aux Catalans de revenir. Mbappé décisif, même si le Kyks a vu Szczesny stopper sa tentative de penalty. Le but refusé de la 12è minute. Une célébration de courte durée. La frustration du hors-jeu semi-automatique ? Autre frustration, celle de Vinicius Jr, remplacé par Rodrygo à 20 minutes de la fin. - Lamine Yamal bien muselé par Alvaro Carreras, une fin de match sous tension. Le Real en profite pour se détacher, compte 5 points d'avance sur son rival catalan.   Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? L'OM s'était installé dans le fauteuil de leader, mais encaisse une 2è défaite d'affilée. Après la déconvenue du Sporting en C1, les Phocéens battus à Lens. Ils n'auront gardé l'avantage que 7 minutes. Nouvelle soirée de cauchemar pour Benjamin Pavard, après celle de Lisbonne mercredi dernier. On n'arrête plus les Sang et Or de Pierre Sage, qui s'emparent de la 2è place, la 10è journée se joue mercredi. Pour débattre avec Hugo Moissonnier, Manu Terradillos, Hervé Penot et Dominique Sévérac. Technique/réalisation : Laurent Salerno - Pierre Guérin.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis's acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences has made a name for itself with its cutting-edge RNA therapeutic technologies, particularly its Antibody Oligonucleotide Conjugates (AOCs). This platform uniquely combines monoclonal antibodies with oligonucleotides, enhancing precision in targeting specific cell types. The integration of Avidity's technology into Novartis's research efforts could accelerate the development of new therapies, potentially transforming patient care with more effective and targeted treatment options. This move not only highlights the industry's focus on specialized therapeutic areas but also anticipates future advances in RNA therapeutics, extending beyond neuromuscular disorders to areas like oncology.In a similar vein, the FDA has shown its willingness to reconsider drugs that previously faced setbacks. GSK's Blenrep has made a return to the U.S. market after receiving approval for treating certain myeloma patients. This approval is particularly noteworthy given the drug's earlier negative advisory committee vote and postponed decision. It marks a significant rebound for GSK's oncology portfolio and reflects the FDA's dynamic approach towards drugs that show potential in specific therapeutic combinations.Meanwhile, Sanofi continues to make waves with Dupixent, achieving over €4 billion in quarterly sales due to its expanded indications. This success contrasts with a decline in Sanofi's vaccine sales, demonstrating shifting dynamics within pharmaceutical portfolios where biologics and specialty drugs are increasingly pivotal. Sanofi's recent financial report highlighted a notable 17% drop in vaccine sales due to reduced demand and pricing challenges in Europe. In response, companies must navigate fluctuating public health demands and economic pressures effectively.On the global stage, efforts to make transformative therapies like Vertex's Trikafta more accessible are gaining momentum through innovative trade-policy workarounds. A buyers club aims to introduce a lower-cost alternative produced by Bangladesh's Beximco, highlighting ongoing challenges and creative strategies in global drug accessibility.Roche's expansion through Chugai's $200 million M&A deal for an IgA nephropathy asset underscores the strategic importance of regional markets in driving growth. Similarly, Lonza's acquisition of a California biologics site aligns with its goals to meet increasing biomanufacturing demands.The industry is also adapting to technological advancements, with AI integration into life sciences commercialization being touted as a frontier for growth. Despite this potential, many organizations remain unprepared to harness AI fully. Leading companies embedding AI solutions aim for measurable outcomes that could significantly drive strategic decision-making and operational efficiencies.Eli Lilly's acquisition of Adverum Biotechnologies aligns with its strategic interests in gene therapy, focusing on promising therapeutic programs that address unmet medical needs. This acquisition centers around Ixo-vec for wet age-related macular degeneration (AMD), highlighting broader industry trends towards investing heavily in innovative therapies that address unmet needs.Conversely, Sanofi's halt on an RSV vaccine development highlights the inherent risks in vaccine development pipelines. Meanwhile, Regeneron's decision to discontinue a CAR T candidate acquired from 2seventy bio showcases ongoing reassessment witSupport the show

In this episode of ASTCT's Titans of Transplant series, Dr. Taha Al-Juhaishi welcomes Dr. Sattva Neelapu of MD Anderson Cancer Center for a deep and insightful conversation on the evolution, challenges and future of CAR T therapy.From the groundbreaking ZUMA-1 trial to today's expandinglandscape of commercial CAR T products, Dr. Neelapu shares pivotal clinical experiences, lessons learned in toxicity management and reflections on mentorship and innovation. This episode offers a look at the progress made, the barriers that remain and the opportunities ahead for the next generation of leaders in cellular therapy.

In this week's episode of the Blood Podcast, Associate Editor Dr. James Griffin interviews Drs. Binod Dhakal and Ruben Bierings about their respective papers published in this week's issue of Blood. Dr. Dhakal presents his study on using talquetamab, a bispecific antibody, as a bridging therapy before BCMA-targeted CAR T-cell therapy in multiple myeloma patients, showing promising results with high response rates and manageable toxicities. Next, Dr. Bierings identified patients with genetic variants in the guanine exchange factor MAP kinase–activating death domain (MADD) that impair VWF secretion from endothelial cells and possibly cause VWD type 1. Featured ArticlesA novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variantsSophie Hordijk, Stijn A. Groten, Petra E. Bürgisser, Sebastiaan N. J. Laan, Georg Christoph Korenke, Tomáš Honzík, Diane Beysen, Frank W. G. Leebeek, Paul A. Skehel, Maartje van den Biggelaar, Tom Carter, Ruben BieringsSequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapyBinod Dhakal, Othman S. Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Darren Pan, Shambavi Richard, Reed Friend, Matthew Rees, Patrick Costello, Mariola Vazquez Martinez, Oren Pasvolsky, Charlotte Wagner, James A. Davis, Omar Castaneda Puglianini, Ran Reshef, Aimaz Afrough, Danai Dima, Manisha Bhutani, Omar Nadeem, Ricardo Parrondo, Ciara Freeman, Lekha Mikkilineni, Shahzad Raza, Larry D. Anderson Jr, Prashant Kapoor, Hitomi Hosoya, Saurabh Chhabra, Ariel Grajales-Cruz, Mahmoud Gaballa, Shonali Midha, Melissa Alsina, Douglas Sborov, Krina Patel, Yi Lin, Christopher Ferreri, Nico Gagelmann, Anupama Kumar, Doris Hansen, Andrew Cowan, Luciano J. Costa, Maximilian Merz, Surbhi Sidana

In this episode, I'm joined by Dr. Burhan Chaudhry, MS neurologist and clinical lead at Bristol Myers Squibb, to discuss CAR-T cell therapy which is an innovative treatment currently enrolling in clinical trials for multiple sclerosis (MS). We dive into how CAR-T cell therapy targets B cells within the central nervous system, offering hope for both relapsing and progressive MS. Dr. Chaudhry explains what sets CAR-T apart from traditional disease modifying therapies, how to get involved in MS clinical trials, and what participants can expect throughout the process. Whether you're newly diagnosed or living with MS for years, join us for empowering strategies, expert advice, and the latest updates on breakthroughs in MS treatment! Bio on Burhan Chaudry: Dr. Burhan Chaudhry is a MS neurologist and clinical lead at Bristol Myers Squibb. His sister was diagnosed with MS when he was in medical school. This inspired him to pursue Neurology. A few years after Burhan was diagnosed with MS as well. After becoming a MS neurologist, Burhan has treated MS patients both in the US and internationally. He is currently clinical lead for a global clinical trial evaluating a novel cell therapy across the MS spectrum. Resources mentioned in this episode: Website to view CAR-T info: https://www.cartautoimmune.com/ ECTRIMS 2025 Results/Report: https://distribute.congrex.com/from.storage?image=rqetJOF1YXChDh_STAPoNpjPhysyG76sohBKnHJhR-TsF3Mvxzx13zdmic5t9umH0 Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

As the potential of in vivo CAR-T therapy moves closer to clinical reality, biotech innovators are reimagining what's possible in autoimmune disease. With groundbreaking scientific advances and evolving regulatory perspectives, this next generation of cell therapy could redefine how immune-mediated conditions are treated. In this episode, Pete Robinson, Therapeutic Strategy Director, Novotech, joins Meredith Landry, Managing Editor, Custom Content, Citeline, to discuss how in vivo CAR-T is opening new possibilities for autoimmune therapies—and what it will take to translate early promise into patient impact. They explore: • The breakthrough potential of in vivo CAR-T—and what could make it a true game-changer for autoimmune disorders • Key developments and considerations to realize clinical success • Global landscape for early phase clinical trials

Just about a month ago, 9,600 researchers, clinicians, and representatives from patient advocacy organizations gathered in Barcelona for the European Committee on Treatment and Research in MS annual scientific congress, better known as ECTRIMS, the largest MS research conference in the world. Now that he's had an opportunity to review his notes and digest all of the science presented at ECTRIMS 2025, Dr. Bruce Bebo, the National MS Society's Executive Vice-President of Research, returns to the podcast to take us on a deep dive covering some of the most important research presented this year. We're also talking about next-generation CAR T-cell therapy for MS, and we'll explain why it's such exciting news. We're sharing details about a DNA-based therapy for overactive bladder that just received fast-track status from the FDA. We'll tell you about a new effort to develop a simple blood test that will detect MS progression. We have some news to share about the RealTalk MS app. And we want to remind you to check out our ECTRIMS Extra Conversations video playlist on the RealTalk MS YouTube channel! We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A deep dive into the research presented at ECTRIMS 2025  :22 Kernal Biologics received $48 million grant for the next-generation CAR T-Cell therapy  2:35 FDA grants fast track designation to DNA-based therapy to treat overactive bladder  6:02 Octave Bioscience receives grant to develop a blood test to detect MS progression  8:30 News about our app  9:42 Have you checked out our ECTRIMS Extra Conversations YouTube playlist?  10:30 Dr. Bruce Bebo discusses some of the most important research presented at ECTRIMS 2025  11:06 Share this episode  32:26 Next week's episode  32:47 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/425 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy LISTEN: RealTalk MS Ep 422: From ECTRIMS 2025 with Dr. Bruce Bebo and Kristine Werner Ozug https://realtalkms.com/422 WATCH: The RealTalk MS ECTRIMS Extra Conversations video playlist on YouTube https://realtalkms.com/ectrims2025 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms DOWNLOAD: The RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 DOWNLOAD: The RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 425 Guests: Dr. Bruce Bebo Privacy Policy

Cartógrafo, major e explorador, Percy Fawcett percorreu alguns dos lugares mais inóspitos do planeta. Em sua juventude, no Sri Lanka, explorou baías remotas e identificou ruínas de antigos reinos budistas.Quando adulto, trabalhou como espião para a Grã-Bretanha, investigando o sultão do Marrocos em Fez.Mas foi na Amazônia tornou-se famoso: Fawcett liderou expedições pelo Acre e pela Bolívia, ajudando a definir as fronteiras entre os dois países.Suas jornadas tornaram-se célebres, com seu rosto impresso em capas de jornais e revistas por toda Europa. Um tabloide da época dizia:“Esse é o verdadeiro escoteiro: tomem-o como exemplo! "O prestígio foi tanto que Leonard Darwin, filho de Charles Darwin e presidente da Royal Geographical Society, o levou em turnê para palestrar pela Inglaterra.Com chapéu de feltro, caderno de anotações e um jeito independente de trabalhar, Fawcett acabou se tornando o molde do aventureiro que mais tarde inspiraria personagens como Indiana Jones.Mas...nem todos o viam como um herói. Muitos colegas o consideravam rígido, arrogante e charlatão, um homem obcecado por glória pessoal e convicções quase absolutas sobre o território que explorava.E, de fato, havia muitas coisas sobre a vida de Fawcett que não era divulgada pela mídia geral...

Hello my lovelies and welcome back to another episode of the pod, and another human being who changing the world! This time I am introducing you to Drew Ann Long, change-maker, world-builder and someone who does not believe in the word "NO", especially when one is trying to make this world better, and shinier, for everyone else! Drew is someone who believes deeply in the goodness in others, in her capacity for showing up for others, and oh, yeah, NEVER GIVING UP! To read about Drew and Caroline's Cart, and Caroline's Cause, click here! To connect with her on Facebook, click here! Do yourself a favor, inspire yourself and remember, that each an every one of us has the ability to do BIG THINGS!! Be like Drew, in other words! PLEASE REMEMBER TO RATE AND REVIEW. IT'S A BIG DEAL AND MEANS SO MUCH TO ME! Your bit of beauty is this: this sweet and powerful YouTube video detailing her journey and her refusal to ever give up!

Hello my lovelies and welcome back to another episode of the pod, and another human being who changing the world! This time I am introducing you to Drew Ann Long, change-maker, world-builder and someone who does not believe in the word "NO", especially when one is trying to make this world better, and shinier, for everyone else! Drew is someone who believes deeply in the goodness in others, in her capacity for showing up for others, and oh, yeah, NEVER GIVING UP! To read about Drew and Caroline's Cart, and Caroline's Cause, click here!  To connect with her on Facebook, click here! Do yourself a favor, inspire yourself and remember, that each an every one of us has the ability to do BIG THINGS!! Be like Drew, in other words! PLEASE REMEMBER TO RATE AND REVIEW. IT'S A BIG DEAL AND MEANS SO MUCH TO ME! Your bit of beauty is this: this sweet and powerful YouTube video detailing her journey and her refusal to ever give up!

Análise pós-jogo do BaVi válido pela 28ª rodada da Série A do Campeonato Brasileiro. Vem com a turma! Em jogo recheado de emoções, muitos cartões e grande festa da torcida rubro negra, deu vitória do Vitória! O resultado de 2 a 1 diante do Bahia deixa o Leão mais vivo do que nunca na briga […]

The Alan Cox ShowSee omnystudio.com/listener for privacy information.

The Alan Cox Show

On today episode, Andy & DJ discuss ICE rolling Portland protester away on flatbed cart as Trump says city is burning to the ground, a bloody Mark Sanchez seen stumbling down Indianapolis sidewalk after being stabbed in fight with grease truck driver, and a brand new segment of AI or Nah.

Scott's old Mr. Show buddy Bob Odenkirk returns to talk about Comic Relief 8, the finale of Better Call Saul, and his future focusing on himself. Then, celebrity chef Bobby Flay stops by to talk about his new cooking show. Plus, lawyer Italiano Jones returns to fight for Scott in a mock trial. Originally released as episode 769 on 08/07/2022. Don't forget to check out the Comedy Bang! Bang! Action Figures at shop.figurecollections.com and go to actionfigureseller.com for international purchases. If you want more great episodes of Comedy Bang! Bang! become a subscriber at comedybangbangworld.com. We have all of the past episodes from the archives, every live show, ad-free new episodes, and original shows like CBB Presents and Scott Hasn't Seen. Find more great Comedy Bang! Bang! merch at https://www.podswag.com/collections/comedy-bang-bang Get access to all the podcasts you love, music channels and radio shows with the SiriusXM App! Get 3 months free using this show link: https://siriusxm.com/cbb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.